Figure 1. Research Method Flow Chart 10
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 15
Figure 4. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 17
Figure 5. Impact of COVID-19 on Business 20
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market 22
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 25
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market 26
Figure 9. Investment Opportunity Analysis 30
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market 33
Figure 11. Breakdown of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue 37
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%) 38
Figure 13. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn 39
Figure 14. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn 41
Figure 15. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn 42
Figure 16. Breakdown of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue 43
Figure 17. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%) 44
Figure 18. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn 45
Figure 19. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn 46
Figure 20. Breakdown of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue 48
Figure 21. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 48
Figure 22. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn 49
Figure 23. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn 50
Figure 24. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn 51
Figure 25. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn 52
Figure 26. Breakdown of APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 54
Figure 27. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 55
Figure 28. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in China, 2017-2027, $ mn 56
Figure 29. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Japan, 2017-2027, $ mn 59
Figure 30. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in India, 2017-2027, $ mn 61
Figure 31. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Australia, 2017-2027, $ mn 63
Figure 32. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in South Korea, 2017-2027, $ mn 65
Figure 33. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC, 2017-2027, $ mn 67
Figure 34. Growth Stage of Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period 69
Asia Pacific amyotrophic lateral sclerosis treatment market will grow by 8.0% annually with a total addressable market cap of $1,244.1 million over 2021-2027 owing to the rising geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies. Highlighted with 28 tables and 34 figures, this 85-page report “Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country. Based on Treatment Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Medication • Riluzole (Rilutek) • Radicava (Edaravone) • Tiglutik (Thickened Riluzole) • Nuedexta • Stem Cell Therapy • Other Treatments Based on ALS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Sporadic ALS • Familial ALS Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Other Distribution Channels Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AB Science SA Amylyx Pharmaceuticals Inc. Biogen Inc. Biohaven Pharmaceutical Holding Co., Ltd. BrainStorm Cell Limited Corestem, Inc. F.Hoffmann-La Roche AG Ionis Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Otsuka Pharmaceutical Co., Ltd. Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More